Best Retatrutide Telehealth Providers for Weight management and metabolic health
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Reviewed by Dr. James Okafor, PharmDPharmDWhat is Retatrutide Used For?
- ✓Weight loss
- ✓Metabolic health
- ✓Appetite suppression
- ✓Blood sugar regulation
How Retatrutide Works
Retatrutide is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component — absent in tirzepatide — provides additional metabolic benefits: glucagon activates brown adipose tissue (increasing energy expenditure), enhances hepatic fat metabolism, and contributes to the appetite suppression effect. Phase 3 data show average weight loss of 22–24% at 48 weeks, with some patients losing 30%+.
What to Expect
Phase 3 TRIUMPH trials show weight loss beginning rapidly — roughly 5% in the first 4 weeks at higher doses. Average weight loss exceeds tirzepatide at 48 weeks (22–24% vs. 20–22%). The additional glucagon component appears to accelerate fat oxidation, producing faster early weight loss than GLP-1 alone or GLP-1/GIP combinations.
Common Side Effects
- ⚠Nausea (common during titration)
- ⚠Vomiting
- ⚠Diarrhea
- ⚠Constipation
- ⚠Decreased appetite
- ⚠Potential: more pronounced GI side effects due to glucagon component at higher doses
This is not a complete list of side effects. Always consult your prescribing physician before starting Retatrutide.
Frequently Asked Questions About Retatrutide
Is retatrutide FDA-approved?▾
As of 2025, retatrutide (LY3437943, Eli Lilly) is in Phase 3 clinical trials. It is not yet FDA-approved. It is available through investigational access and some compounding pharmacies, though availability may be limited and regulatory status is evolving.
How does retatrutide compare to tirzepatide?▾
Phase 3 data suggest retatrutide produces 3–5% more total weight loss than tirzepatide at 48 weeks, and with faster early weight loss due to the glucagon component. However, it may have slightly more GI side effects. Neither drug has been directly compared head-to-head in a Phase 3 trial.
Is the glucagon component in retatrutide safe?▾
Glucagon activates hepatic glucose production, which sounds counterintuitive for a diabetes or metabolic drug. However, the GLP-1 component simultaneously suppresses glucagon's blood-glucose-raising effect, so the net glycemic impact is still favorable. The glucagon component primarily contributes through increased energy expenditure and lipolysis.
Who is retatrutide best suited for?▾
Retatrutide targets patients with severe obesity (BMI ≥35) where maximum weight loss is the primary goal, or patients who have had suboptimal response to semaglutide or tirzepatide. Given its investigational status as of 2025, it is typically recommended only by providers experienced with off-label peptide prescribing.
3 Providers Offering Retatrutide
Sorted by lowest price first.
| Provider | Price | Dose | Rating | Consultation | Lab Testing |
|---|---|---|---|---|---|
| Defy Medical Tampa, FL | $450/monthly | Protocol varies | 4.1/5 | Video Telehealth | Included |
| Evolve Telemed San Diego, CA | $480/monthly | Protocol varies | 4/5 | Video Telehealth | Included |
| TruLife Health Scottsdale, AZ | $550/monthly | Protocol varies | 4.1/5 | Video Telehealth | Included |